secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0001628280-23-007432
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin cuts 70% of workforce, CEO to resign as company seeks strategic alternatives
--------------------------------------------------------------------------------

- Board approved 70% workforce reduction and re-prioritization to seek strategic alternatives to maximize shareholder value.
- Estimated restructuring costs between $2.5M and $3.0M, primarily severance and benefits, with $0.3M non-cash.
- CEO Jonathan Drachman resigns as President, CEO and director effective March 31, 2023; no replacement announced.
- Severance includes 12-month salary continuation, 3-month target cash bonus, accelerated option vesting of August 2022 grant.
- Execution of restructuring expected substantially complete by end of Q2 2023; costs incurred in first half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023007432/0001628280-23-007432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023007432/nltx-20230306.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-007432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer